(MedPage Today) — FDA cleared the Elecsys pTau181 test as the first blood-based biomarker to aid in the initial assessment of Alzheimer’s disease and other causes of cognitive decline that can be used in the primary care setting, Roche announced…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/117920
Author :
Publish date : 2025-10-13 18:23:00
Copyright for syndicated content belongs to the linked Source.
